Last reviewed 2026-04-20 · How we verify

Arm 2 Hydrocortisone 30 mg

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Hyperglycaemia
• Nausea
• Diarrhoea
• Headache
• Nasopharyngitis
• Abdominal pain
• Alanine aminotransferase increased
• Vomiting
• Fatigue
• Cholelithiasis
• Diabetes mellitus
• Dizziness

Key clinical trials

• Platform of Randomized Adaptive Clinical Trials in Critical Illness (NA)
• V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency (PHASE3)
• ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (PHASE3)
• PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (PHASE1, PHASE2)
• Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety (PHASE1, PHASE2)
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors (PHASE1, PHASE2)
• Amphotericin Versus Posaconazole for Pulmonary Mucormycosis (PHASE2)
• EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Arm 2 Hydrocortisone 30 mg CI brief — competitive landscape report
• Arm 2 Hydrocortisone 30 mg updates RSS · CI watch RSS
• Central Institute of Mental Health, Mannheim portfolio CI